As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead liver-targeting gene therapy into human trials. | As other gene editing programs ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Septerna, Inc. ("Septerna" or "the Company") for violations of ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company ...

Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics ...

Collaboration Revenue: There was $2.3 million of collaboration revenue for the year ended December 31, 2024, as compared to no collaboration revenue for the year ended December 31, 2023. The increase ...

NIST's fecal RM helps standardize microbiome research to ensure accuracy, consistency, comparability, and reproducibility in the field.

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Q4 2024 Earnings Call Transcript March 17, 2025 Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.11 EPS, expectations were $-0.09. Operator: Good afternoon, and welcome ...

Oysters Candy is a premium fitness complement designed by way of 11Oysters to offer an amazing mixture of natural elements for greater vitality, performance, and standard well-being. Combining the ...

Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...

Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS.